特此公告。 上海凯宝药业股份有限公司（以下简称"公司"）监事会于近日收到公司职工 代表监事路发凯先生的书面离职申请，其因个人原因，申请辞去公司第六届监事会 职工代表监事职务。辞任后，路发凯先生不再担任本公司任何职务。上述职务的原 定任期至公司第六届监事会任期届满之日止。 根据《公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市 公司规范运作》《公司章程》等有关规定，路发凯先生的离职，将导致公司监事会 成员中职工代表监事人数少于监事会成员的三分之一，因此，其离职申请将在公司 补选出新的职工代表监事后方可生效，在此之前，路发凯先生将继续按照有关规定 和要求履行其作为职工代表监事的相关职责。公司将按照有关规定尽快完成职工监 事的补选工作。 截止本公告披露日，路发凯先生未持有公司股票，亦不存在应当履行而未履行 的承诺事项。 证券代码：300039 证券简称：上海凯宝 公告编号：2025-005 上海凯宝药业股份有限公司 关于职工代表监事离职的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司监事会 2025 年 2 月 17 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2025-004 上海凯宝药业股份有限公司 苓桂术甘汤颗粒获得国家药监局《药品注册证书》，进一步丰富了公司产品线， 有助于提升公司产品的市场竞争力，促进了古代经典名方新药转化及其在现代临床 中的广泛应用。 鉴于该产品新获药品注册证书，其生产和销售受国家政策、市场环境等因素影 响，具有不确定性。敬请广大投资者理性投资，注意投资风险。 关于获得药品注册证书的公告 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"、"上海凯宝"）近日收到国家 药品监督管理局签发的苓桂术甘汤颗粒《药品注册证书》。具体情况如下： | 药品名称 | 苓桂术甘汤颗粒 | | --- | --- | | 剂型 | 颗粒剂 | | 规格 | 每袋相当于饮片 27.6g | | 包装规格 | 每袋装 8g，每盒装 20 袋 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 中药 3.1 类 | | 药品有效期 | 24 个月 | | 处方药/非处方药 | 处方药 | | 证书 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2024-040 上海凯宝药业股份有限公司关于公司及子公司 产品在国家医保目录（2024 年）中调整情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 2024 年 11 月 28 日，国家医保局、人力资源社会保障部发布《关于印发<国家基本 医疗保险、工伤保险和生育保险药品目录(2024 年)>的通知》（医保发〔2024〕33 号）， 公布了《国家基本医疗保险、工伤保险和生育保险药品目录（2024 年）》（以下简称 《国家医保目录（2024 年）》）。 上海凯宝药业股份有限公司（以下简称"公司"）及全资子公司上海凯宝新谊（新 乡）药业有限公司（以下简称"子公司"、"新谊药业"）共有 91 个药品纳入国家医 保目录，其中甲类 50 个，乙类 41 个。主要涉及独家品种 3 个(公司产品痰热清注射液、 痰热清胶囊，子公司产品芪参胶囊)，独家剂型 1 个（公司产品多索茶碱胶囊）等继续 进入《国家医保目录（2024 年）》。现将有关调整情况公告如下： 一、公司及子公司产品调整情况 公司产品盐酸吡格列酮片调出 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2024-039 上海凯宝药业股份有限公司关于 项目主要完成单位：上海市食品药品检验研究院、上海凯宝药业股份有限公司、 上海万仕诚药业有限公司、上海上药杏灵科技药业股份有限公司、武汉大鹏药业有 限公司、石家庄以岭药业股份有限公司。 近日，上海市科技大会暨科学技术奖励大会在上海召开。上海凯宝药业股份有 限公司（以下简称"公司"）、穆竟伟董事长参与完成的"中药全产业链质量控制 技术创新与支撑体系构建及应用"项目获得 2023 年度上海市科技进步奖一等奖。有 关情况如下： 一、基本情况 奖项名称：2023 年度上海市科技进步奖一等奖 "中药全产业链质量控制技术创新与支撑体系构建及应用"项目，围绕中药质 量的关键问题，对中药安全性和内在质量控制技术方法、全过程标准化体系、数据 库及支撑平台等开展研究，创建了中药中两千余种外源性有毒有害物质控制技术等 综合应用的中药复杂成分检测方法，构建了中药大品种全过程标准化及质量追溯体 系，打造了中药质量控制数据库及产学研医融合技术平台。 公司始终将产品质量与安全作为发展的第一要务，不断强化新技术研发、生产 质量管理和安全管理的 ...

Financial Performance - The company's revenue for Q3 2024 was ¥292,085,545.44, a decrease of 5.16% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was ¥74,929,468.45, an increase of 23.16% year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥69,025,506.03, up 14.47% from the previous year[3]. - The company reported a total operating revenue of ¥1,121,237,259.68 for the current period, a decrease of approximately 2.0% compared to ¥1,154,328,501.63 in the previous period[18]. - The net profit for the current period was ¥216,637,804.54, representing an increase of about 10.6% from ¥195,830,856.66 in the previous period[19]. - The net profit attributable to the parent company for Q3 2024 was ¥217,068,484.50, an increase from ¥196,123,448.91 in the same period last year, representing a growth of approximately 10%[20]. - The total comprehensive income attributable to the parent company was -¥72,930,259.28, compared to ¥122,556,994.92 in the previous year, indicating a significant decline[20]. - The basic and diluted earnings per share for Q3 2024 were both ¥0.2075, up from ¥0.1875 in Q3 2023, reflecting an increase of about 11%[20]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥4,327,782,207.53, reflecting a decrease of 5.50% from the end of the previous year[3]. - The total current assets increased to ¥2,014,501,423.92 from ¥1,474,882,585.47, reflecting a growth of approximately 36.5%[16]. - The total liabilities decreased to ¥472,886,749.53 from ¥546,816,517.96, a reduction of about 13.5%[17]. - The company’s total assets decreased to ¥4,327,782,207.53 from ¥4,579,672,915.20, a decline of about 5.5%[17]. - The company’s equity attributable to shareholders decreased to ¥3,853,687,198.23 from ¥4,031,217,457.51, a decrease of approximately 4.4%[17]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥259,185,867.28, down 10.61% compared to the same period last year[3]. - Cash inflows from operating activities totaled ¥1,387,829,100.72, slightly down from ¥1,427,859,744.64 in the previous year[21]. - The net cash flow from operating activities was ¥259,185,867.28, compared to ¥289,951,827.18 in the same period last year, showing a decrease of approximately 10%[22]. - Cash outflows from investing activities amounted to ¥1,171,093,654.75, down from ¥1,739,183,565.83 in the previous year, indicating a reduction of about 32%[22]. - The net cash flow from investing activities was -¥116,442,663.27, compared to -¥4,405,686.72 in the previous year, reflecting a worsening situation[22]. - The net cash flow from financing activities was -¥101,624,700.83, compared to -¥62,760,000.00 in the previous year, indicating an increase in cash outflows[23]. - The cash and cash equivalents at the end of the period were ¥476,872,688.80, down from ¥537,266,310.62 at the end of the previous year[23]. - The company's cash and cash equivalents reached ¥1,203,072,688.80, up from ¥601,944,185.62, indicating a significant increase of approximately 99.7%[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 58,124, with the top 10 shareholders holding a combined 40.73% of shares[8]. - The largest shareholder, Mu Jingwei, holds 16.06% of shares, amounting to 168,029,270 shares[8]. - The second-largest shareholder, Zhang Yanqi, holds 15.37% of shares, totaling 160,790,370 shares[8]. - The company has a total of 126,021,952 shares under lock-up for the largest shareholder, Mu Jingwei, due to executive lock-up restrictions[13]. - The total number of shares held by the top 10 unrestricted shareholders is 303,000,000 shares[8]. - The company reported a total of 3,600,000 shares held by Chen Xuanjiang, which are unrestricted ordinary shares[9]. - The total number of shares under lock-up for executives at the end of the reporting period is 129,073,774 shares[13]. - The company has seen a change in the number of shares held by the top 10 shareholders due to financing and securities lending activities[10]. - The total number of shares held by the top 10 shareholders participating in securities lending is 3,997,500 shares, representing 0.38% of total shares[11]. - The company has a total of 7,405,900 shares held by another major shareholder, representing 0.71% of total shares[12]. Research and Development - Research and development expenses increased by 33.29% year-over-year, indicating a focus on enhancing R&D capabilities[6]. - Research and development expenses for the current period were ¥102,273,749.63, an increase of 33.3% compared to ¥76,729,257.45 in the previous period[19].

证券代码：300039 证券简称：上海凯宝 公告编号：2024-036 上海凯宝药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"、"上海凯宝"）第六届董事 会第三次会议、2023 年年度股东大会审议通过了《关于使用闲置自有资金进行委托 理财额度的议案》，在保证日常经营运作资金需求、有效控制投资风险的情况下， 同意公司及子公司使用闲置自有资金购买理财产品额度不超过人民币 8 亿元，其年 累计发生额不超过人民币 60 亿元，购买理财产品的额度自股东大会审议通过之日起 12个月内可滚动使用。同时，在上述额度范围内授权管理层具体实施委托理财事宜， 包括但不限于委托理财的形式、期限及金额等。公司独立董事、监事会均发表了同 意的意见。具体内容详见公司于 2024 年 4 月 26 日、2024 年 6 月 5 日在巨潮资讯网 披露的相关公告。 截至本公告日，公司根据经营情况在以上决议授权范围内，使用闲置自有资金 进行银行理财产品、国债逆回购等委托理财事项，现就具体内容公 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2024-035 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，上海凯宝药业股份有限公司（以下简称"公 司"）将参加由上海上市公司协会与深圳市全景网络有限公司联合举办的"2024 年 上海辖区上市公司投资者集体接待日暨中报业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net/html/143790.shtml），或关注微信公众号：全景财经，或 下载全景路演 APP,参与本次互动交流，活动直播时间为 2024 年 9 月 13 日（周五） 14:00-16:30。 届时公司董事、总经理周迎宾先生，董事、董事会秘书任立旺先生将在线就公 司 2024 年度中报业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投 资者进行沟通与交流，欢迎广大投资者踊跃参与！ 上海凯宝药业股份有限公司关于 参加上海辖区上市公司 2024 年投资者 网上集体接待日暨中报业绩说明会的公告 上海凯宝药 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2024-032 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"）第六届董事会第五次会议通 知于 2024 年 8 月 17 日以邮件、书面的方式送达全体董事。会议于 2024 年 8 月 28 日上午在公司会议室以现场和通讯相结合的方式召开，会议应参会董事九名，实际 参会董事九名。本次会议召开符合《公司法》等相关法律法规和《公司章程》、《公 司董事会议事规则》的有关规定。会议由董事长主持，经全体董事审议和表决，通 过以下决议： 一、审议通过了《2024 年半年度报告》及《2024 年半年度报告摘要》 公司《2024 年半年度报告》及《2024 年半年度报告摘要》内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见中国证监会指定的创业板信息披露网站上的相关公告。 上海凯宝药业股份有限公司 表决结果：同意 9 票、反对 0 票、弃权 0 票。 三、审议通过了《关于变更公司财务总监的议 ...

| | 上海顺捷医药有限公司 | 孙子公司 | 其他应 收款 | | 521.25 | 521.25 | | 拆借利息 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 上市公司的子 公司及其附属 | 上海顺捷医药有限公司 | 孙子公司 | 应收账 款 | 37,659.33 | 37,562.75 | 62,051.71 | 13,170.37 | 销售商品 | 经营性往来 | | | 上海凯宝健康科技有限公司 | 子公司 | 预付账 | | 0.04 | 0.04 | | 采购商品 | 经营性往来 | | 企业 | | | 款 | | | | | | | | | 上海凯合交医疗科技有限公司 | 子公司 | 预付账 | | 7.50 | 7.50 | | 采购商品 | 经营性往来 | | | | | 款 | | | | | | | | | 上海凯合交医疗科技有限公司 | 子公司 | 其他应 | 1.11 | | 1.11 | | 代垫款 | 非经营性往来 | | | | | 收款 | | | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥829,151,714.24, a decrease of 2.03% compared to ¥846,347,925.21 in the same period last year[11]. - Net profit attributable to shareholders of the listed company increased by 5.07% to ¥142,139,016.05 from ¥135,286,640.78 year-on-year[11]. - The net profit after deducting non-recurring gains and losses rose by 10.74% to ¥142,818,008.61 compared to ¥128,965,216.90 in the previous year[11]. - The net cash flow from operating activities decreased by 26.84% to ¥131,071,740.10 from ¥179,156,086.88 in the same period last year[11]. - Basic and diluted earnings per share increased by 5.10% to ¥0.1359 from ¥0.1293 year-on-year[11]. - Total assets at the end of the reporting period were ¥3,970,908,394.51, down 13.29% from ¥4,579,672,915.20 at the end of the previous year[11]. - Net assets attributable to shareholders of the listed company decreased by 12.95% to ¥3,509,353,208.88 from ¥4,031,217,457.51 at the end of the previous year[11]. - The company reported a significant decline in net cash increase of 139.80%, totaling -¥91,384,888.34, due to reduced cash inflow from investment activities[34]. - The company achieved operating revenue of 829.15 million yuan in the first half of 2024, a decrease of 2.03% compared to the same period last year[24]. - The net profit attributable to shareholders of the listed company was 142.14 million yuan, an increase of 5.07% year-on-year[24]. Research and Development - The company is advancing its innovative traditional Chinese medicine research, with some products in clinical phases II and III[18]. - The company has received 3 government project grants during the reporting period, enhancing its research capabilities[17]. - The company established a joint research center with Shanghai Jiao Tong University to enhance collaboration in technology research and development[21]. - The company is committed to increasing R&D investment to enhance its core competitiveness and has established an innovation drug research institute[25]. - Research and development investment increased by 27.78% to ¥75,927,815.64, indicating a focus on innovation[34]. - The company is focused on sustainable development by researching alternative drugs to protect endangered medicinal materials[28]. - The company is enhancing its marketing system and optimizing sales channels to improve market coverage and brand competitiveness[25]. Market Expansion and Product Development - The company is actively expanding its market presence through its subsidiary, ShunJie Pharmaceutical, which has established a strong sales and promotion platform across various regions[18]. - The company aims to leverage existing product potential for market promotion, seeking new profit growth points[18]. - The company is expanding its product pipeline by accelerating the development of its main product and exploring new product introductions in the health sector[25]. - The company is focused on strategic initiatives to improve financial performance and shareholder value in the upcoming periods[135]. - The company plans to enhance its product line by focusing on the development of health-related products and accelerating the secondary development of core products to reduce reliance on single products[64]. Financial Strategy and Investments - The company focuses on investment opportunities in high-quality enterprises in traditional Chinese medicine and biopharmaceuticals, particularly in respiratory, cardiovascular, and digestive systems[19]. - The company has not engaged in high-risk investments or provided financial assistance to others in the past twelve months[54]. - The company has not engaged in derivative investments or entrusted loans during the reporting period, indicating a conservative financial strategy[60][61]. - The company plans to use 400 million CNY of remaining raised funds for the independent research and development of the "Dinggui Oil Soft Capsule" project[54]. - The company has a structured approach to remeasure lease liabilities and adjust corresponding right-of-use assets based on changes in lease terms or payment amounts[194]. Compliance and Governance - The company has not experienced any penalties or rectifications during the reporting period, indicating a stable compliance status[78]. - The company has not encountered any issues with the rationality and compliance of its raised funds usage and information disclosure[55]. - The company has successfully maintained compliance with environmental discharge standards, with no exceedances reported[72]. - The company has no significant litigation or arbitration matters during the reporting period[76]. - The company has not reported any changes in the use of raised funds during the reporting period[56]. Shareholder Information - The total number of shares before the recent change was 1,046,000,000, with no new shares issued or stock dividends distributed[96]. - Major shareholders include Mu Jingwei with 16.06% (168,029,270 shares) and Zhang Yanqi with 15.37% (160,790,370 shares)[99]. - The total number of shareholders at the end of the reporting period was 60,054[97]. - The company has not issued any new shares or conducted any stock buybacks during the reporting period[96]. - The report indicates no significant changes in the shareholding structure among major shareholders[99]. Environmental and Social Responsibility - The company invested CNY 1.4359 million in environmental governance and paid CNY 16,700 in environmental protection tax during the first half of 2024[73]. - The company has a wastewater treatment capacity of 1,000 tons per day, ensuring compliance with discharge standards[73]. - The company provided CNY 50,000 in aid to the local community in Yunnan Province for improving public service facilities[75]. Financial Reporting and Accounting Policies - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance and reflect the company’s financial position as of June 30, 2024[144]. - The company’s accounting policies and estimates are tailored to its operational characteristics, with specific disclosures regarding revenue recognition[143]. - The company recognizes expected credit losses for financial assets measured at amortized cost and those measured at fair value with changes recognized in other comprehensive income, based on reasonable and supportable information[159]. - The company assesses the recoverability of deferred tax assets and may adjust their carrying value if future taxable income is insufficient[190].